Bio Pharma

  • Home
  • Products
  • Liraglutide (API) to accelerate Diabetic therapy from Lorven Biologics

Liraglutide (API) to accelerate Diabetic therapy from Lorven Biologics

Background

  • Liraglutide is used as a long-acting glucagon-like peptide-1 receptor agonist and it regulates the  insulin secretion.
  • Until recently there is no academia and biotechnology companies having a recombinant DNA based peptide technology.
  • Our technology on Liraglutide would benefit many pharma majors to decrease their cost of peptides production.

Salient features Lorven’s Liraglutide

  • Application ready Liraglutide Biosimilar from Yeast.
  • High pure (96%), available at an economical price .
  • Lorven’s Liraglutide is expressed in our bioengineered Yeast expression system.
  • Direct secretion of active peptide into the growth media.
  • Endotoxin free secretion system.
  • Yields up to gm/lit/hour.
  • Reduced production cost and speed time to market.

Product Quality

  • Biosimilar to Liraglutide (Novo Nordisk).
  • 100% native confirmation.
  • Functionally active peptide.
  • Free from animal-derived components.

Safety

  • Saccharomyces : Genetically  highly  amenable  host  organism with BSL-1 maintenance.

IP

  • Patent Application Under process:
  • Title: Process for improved expression of biologically active Liraglutide in Yeast expression system by strain engineering.